Overview

Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma

Status:
RECRUITING

Trial end date:
2030-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.

Phase:

PHASE2

Details

Lead Sponsor:

University of Utah

Collaborator:

ADC Therapeutics S.A.

Treatments:

loncastuximab tesirine
Rituximab